Zepbound News — every source, one live feed
Track Zepbound news in real time — Lilly's obesity-branded tirzepatide leading the weight-loss market. fllwup^ collects the latest Zepbound headlines from every major source into one live feed — free, no account, no algorithm. Coverage aggregated from BBC, Reuters, AP, NYT, TechCrunch, Al Jazeera, and 200+ other outlets.
Latest Zepbound headlines
- 2 Patients Have Been Hospitalized With Psychosis or Mania After Abruptly Stopping GLP-1s — ScienceAlert
- Here’s what’s been proven to help GLP-1 users from losing too much muscle from the drug — MarketWatch
- US FDA orders new eye risk warnings for Ozempic, Zepbound — CNN
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity — PR Newswire
- Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns — Fox News
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound — CNBC
- Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial — STAT
- Experimental Lilly combination drug tops Zepbound in weight-loss trial — Reuters
- Lilly raises diabetes weight-loss bar with amylin-Zepbound combo — Fierce Biotech
- Novo’s next-gen weight-loss drug outperforms Zepbound in new trial — NewsNation
Follow Zepbound live on fllwup^ · Follow in any RSS reader — or browse all topics.
More Health & Medicine: browse the category. Compare: fllwup^ vs Flipboard · vs Feedly · vs Google News · vs Apple News.